EuroPCR 2016 Roundup: TAVR innovations, FFR systems in the spotlight
St. Jude Medical (NYSE:STJ) announced it won CE Mark approval in the European Union for its PressureWire X Guidewire fractional flow reserve measurement system and is launching the product in Europe. The company announced the launch and clearance at the EuroPCR meeting in Paris this week. “Fractional flow reserve has become an indispensable tool for assessing coronary lesions and making informed treatment decisions during percutaneous coronary intervention. The improved design of the new PressureWire X guidewire tip will simplify the fractional flow reserve procedure by enabling access to lesions in patients wit...
Source: Mass Device - May 18, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Drug-Eluting Stents Replacement Heart Valves Stent Grafts Biotronik Edwards Lifesciences EuroPCR 2016 InspireMD Leerink Partners Medinol Ltd Reva Medical Inc. St. Jude Medical Source Type: news

EuroPCR 2016 Update: TAVR innovations, FFR systems in the spotlight
UPDATED May 20, 2016, with more results out of Paris. St. Jude Medical (NYSE:STJ) announced it won CE Mark approval in the European Union for its PressureWire X Guidewire fractional flow reserve measurement system and is launching the product in Europe. The company announced the launch and clearance at the EuroPCR meeting in Paris this week. “Fractional flow reserve has become an indispensable tool for assessing coronary lesions and making informed treatment decisions during percutaneous coronary intervention. The improved design of the new PressureWire X guidewire tip will simplify the fractional flow reserve p...
Source: Mass Device - May 18, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Clinical Trials Drug-Eluting Stents Replacement Heart Valves Stent Grafts Biotronik Edwards Lifesciences EuroPCR 2016 InspireMD Leerink Partners Medinol Ltd Reva Medical Inc. St. Jude Medical Source Type: news

Sleep Apnea May Raise Risks for Angioplasty Patients
Title: Sleep Apnea May Raise Risks for Angioplasty PatientsCategory: Health NewsCreated: 5/16/2016 12:00:00 AMLast Editorial Review: 5/17/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - May 17, 2016 Category: Cardiology Source Type: news

2016: Optimal imaging matches intravascular ultrasound for guiding PCI EuroPCR
(PCR) The first study to compare optimal frequency domain imaging (OFDI) with intravascular ultrasound (IVUS) to guide percutaneous coronary intervention (PCI) shows equivalent clinical outcomes with both imaging techniques. The study authors say the positive findings for OFDI support a class IIa recommendation in guidelines. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2016 Category: Global & Universal Source Type: news

EuroPCR 2016: Polymer-free coronary stent more effective & safer than BMS in ACS patients
(PCR) Results from a prespecified sub-study of the LEADERS FREE trial in patients with acute coronary syndromes and high risk for bleeding show lower rates of target lesion revascularisation and fewer adverse events after undergoing percutaneous coronary intervention with a polymer-free drug-coated stent than with a bare metal stent. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2016 Category: Global & Universal Source Type: news

Orthofix Announces 510(k) Clearance and US Limited Market Launch of FORZA PTC Interbody Spacer System
LEWISVILLE, Texas--(Healthcare Sales & Marketing Network)--Orthofix International N.V. (OFIX), a diversified, global medical device company, today announced the 510(k) clearance and U.S. limited market launch of the FORZA® PTC™ (Peek Titanium Composite... Devices, Orthopaedic, Neurosurgery, FDAOrthofix International, FORZA PTC, interbody spacers, spine surgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 16, 2016 Category: Pharmaceuticals Source Type: news

Sleep Apnea May Raise Risks for Angioplasty Patients
MONDAY, May 16, 2016 -- Scientists say they now have more evidence that sleep apnea might worsen heart disease. Sleep apnea leads to interrupted breathing during sleep. In their study, the researchers found that patients with the condition who had... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 16, 2016 Category: Journals (General) Source Type: news

Philips Volcano Activities at EuroPCR
At this year's EuroPCR meeting in Paris, Philips will be celebrating the one-year anniversary of its partnership (read "acquisition") of Volcano Corporation, making it the only cath lab imaging manufacturer able to offer intravascular options such as intravascular ultrasound (IVUS), fractional flow reserve (FFR) and its own proprietary non-adenosine functional measurement technology, iFR. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 15, 2016 Category: Cardiology Source Type: news

Cath Lab Recap: PAD Balloon Angioplasty; 'Hybrid' PCI
(MedPage Today) -- Interventional cardiology news to note (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 13, 2016 Category: Cardiology Source Type: news

Young women at greater risk for adverse outcomes following PCI
Women younger than 55 years of age who undergo percutaneous coronary intervention for acute coronary syndrome are more likely to experience one-year adverse cardiovascular events due to risk factors such as diabetes and chronic kidney disease, yet they are less likely to receive potent antiplatelet therapy than men. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 6, 2016 Category: Science Source Type: news

Medtronic touts multi-trial In.Pact Admiral data
Medtronic (NYSE:MDT) today released a bevy of new data from clinical studies of its In.Pact Admiral drug coated balloon designed for treating peripheral artery disease. The Fridley, Minn.-based released data from 3 different studies of its In.Pact Admiral DCB at the 2016 Charing Cross Symposium meeting in London, including 1-year results from a chronic total occlusion imaging cohort and 2-year gender and diabetic subgroup analysis. “The In.Pact Admiral drug-coated balloon’s unique coating delivers paclitaxel in a solid state which results in durable tissue levels of drug leading to prolonged anti-rest...
Source: Mass Device - April 26, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Medtronic Source Type: news

Ocular Complications After Cardiac InterventionOcular Complications After Cardiac Intervention
Retinal artery occlusion is a potential complication of percutaneous coronary intervention. Find out what there is to know. BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 26, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Reasons for hospital-level variations in bleeding post-angioplasty are unclear
The use of bleeding avoidance strategies has only a modest effect on the variation in bleeding rates post-angioplasty among hospitals performing this procedure, leaving about 70 percent of the causes for this variation unexplained, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 18, 2016 Category: Science Source Type: news

New heart attack treatment saves 30 lives a year, HSE says
92% of patients will soon be within required 90 minutes of livesaving angioplasty treatment (Source: The Irish Times - Health)
Source: The Irish Times - Health - April 15, 2016 Category: Consumer Health News Source Type: news

FDA clears Abiomed’s Impella with indication for cardiogenic shock
Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval indications for its Impella line of percutaneous heart pumps to treat patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. The Impella devices are now indicated for the stabilization of a patient’s hemodynamics, unloading of the left ventricle, perfusion of the end organs and to allow for recovery of the native heart, according to the Danvers, Mass.-based company. “Abiomed would like to recognize our customers, physicians, nurses, scientists, regulators and employees for their last fifteen years of ci...
Source: Mass Device - April 7, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Pre-Market Approval (PMA) Abiomed Inc. Source Type: news

FDA approves Abiomed’s Impella with indication for cardiogenic shock
Abiomed (NSDQ:ABMD) said today it won expanded FDA premarket approval indications for its Impella line of percutaneous heart pumps to treat patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. The Impella devices are now indicated for the stabilization of a patient’s hemodynamics, unloading of the left ventricle, perfusion of the end organs and to allow for recovery of the native heart, according to the Danvers, Mass.-based company. “Abiomed would like to recognize our customers, physicians, nurses, scientists, regulators and employees for their last fifteen years of ci...
Source: Mass Device - April 7, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Assist Devices Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Pre-Market Approval (PMA) Abiomed Inc. Source Type: news

FDA OK to Medtronic's Micra: World's Smallest and 1st Transcatheter Pacemaker Approved in U.S.
Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval of the world's smallest pacemaker, the Medtronic Micra Transcatheter Pacing System (TPS). The Micra TPS is the first FDA-approved product with miniaturized pacing technology. It is cosmetically invisible and small enough to be delivered through a catheter and implanted directly into the heart -providing a safe alternative to conventional pacemakers without the complications associated with cardiac wires (leads). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 7, 2016 Category: Cardiology Source Type: news

Percutaneous Coronary Intervention Increases Risk of CataractsPercutaneous Coronary Intervention Increases Risk of Cataracts
The risk of cataracts increases after percutaneous coronary intervention (PCI), suggesting the need for eye protection in patients undergoing these procedures, researchers from Taiwan report. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - April 5, 2016 Category: Opthalmology Tags: Internal Medicine News Source Type: news

US prediction models for kidney injury following angioplasty hold up in Japan
Models developed by the American College of Cardiology NCDR CathPCI Registry to predict the likelihood of angioplasty patients developing acute kidney injury and acute kidney injury requiring dialysis have proven to be effective among patients in Japan. This finding suggests these models may have international application as a preventive tool, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 4, 2016 Category: Science Source Type: news

Medtronic Announces Early Data and Completes Enrollment in CE Mark Cohort in Drug-Filled Stent Trial
Medtronic plc (NYSE: MDT) announced new clinical data today from one of the endpoints in the RevElution Trial for its novel, next-generation Drug-Filled Stent (DFS). These new data showed rapid vessel healing without inflammation in Optical Coherence Tomography (OCT) data of the complete one-month follow-up patient cohort. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 3, 2016 Category: Cardiology Source Type: news

Medtronic CoreValve® System Demonstrates Superior Survival to Surgery in Aortic Stenosis Patients with Lower STS Scores
The analysis of the sub-cohort compared 202 patients treated with the CoreValve System against 181 patients who received surgical aortic valve replacement (SAVR). The CoreValve TAVR patients demonstrated superior outcomes in all-cause mortality at two years compared to patients treated with surgical aortic valve replacement (15.0 percent vs. 26.3 percent; p=0.01). In addition, rates of combined all-cause mortality or major stroke were superior for TAVR with the CoreValve System (17.1 percent vs. 31.9 percent; p=0.0018). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 3, 2016 Category: Cardiology Source Type: news

Medtronic CoreValve ® System Demonstrates Superior Survival to Surgery in Aortic Stenosis Patients with Lower STS Scores
The analysis of the sub-cohort compared 202 patients treated with the CoreValve System against 181 patients who received surgical aortic valve replacement (SAVR). The CoreValve TAVR patients demonstrated superior outcomes in all-cause mortality at two years compared to patients treated with surgical aortic valve replacement (15.0 percent vs. 26.3 percent; p=0.01). In addition, rates of combined all-cause mortality or major stroke were superior for TAVR with the CoreValve System (17.1 percent vs. 31.9 percent; p=0.0018). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 3, 2016 Category: Cardiology Source Type: news

Philips Volcano Announces More Than 5,000 Coronary Artery Disease Patients Enrolled in iFR Outcomes Trials
(Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 1, 2016 Category: Cardiology Source Type: news

First Patients Enrolled in Medtronic Trial in Low-Risk Aortic Stenosis Patients
Medtronic plc (NYSE: MDT) today announced that the first patients were enrolled in the expanded indication trial for the CoreValve® Evolut® R System, the first and only next-generation recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system commercially available in the United States. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 1, 2016 Category: Cardiology Source Type: news

Societies Update Guidelines for Dual Antiplatelet Therapy
The American College of Cardiology and the American Heart Association today released updated guidelines for dual antiplatelet therapy in patients with coronary artery disease. In general, duration of dual antiplatelet therapy recommendations in the document consist of a Class I recommendation of “should be given” for a minimum time period of time (usually six to 12 months). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 30, 2016 Category: Cardiology Source Type: news

FDA clears Corindus Vascular Robotics CorPath for peripheral interventions
Corindus Vascular Robotics (NYSE:CVRS) said today that it won FDA 510(k) clearance for its robotic-assisted CorPath system for peripheral interventions, a year after launching a clinical trial. The clearance was based on the 20-patient Rapid trial, a prospective, single-arm, single-center study designed to look at the safety and effectiveness of the CorPath device in peripheral artery disease patients with lower-extremity blockages. “For the past 2 years, I have been successfully treating my coronary patients with robotic precision while protecting my staff and me from the hazards of rad...
Source: Mass Device - March 29, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Robot-Assisted Surgery Corindus Vascular Robotics Peripheral Artery Disease Source Type: news

Opsens Receives FDA 510(K) Clearance for the OptoWire II
This approval allows Opsens to market the OptoWire II in the world’s largest market. The OptoWire II is a new design comprising a hydrophilic coating that further improves the performances of the guidewire in different scenarios, such as in highly calcified and tortuous vessels. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 29, 2016 Category: Cardiology Source Type: news

Abiomed, FDA come to terms on Impella PMA requirements
Abiomed (NSDQ:ABMD) said yesterday that it came to terms with the FDA over the indications for use for its Impella line of cardiac assist devices and doesn’t believe it will have to appear before 1 of the agency’s advisory panels. Danvers, Mass.-based Abiomed said the federal safety watchdog agreed on the indication for treating patients in cardiogenic shock after a heart attack or cardiac surgery with its Impella 2.5, Impella CP, Impella 5.0 and Impella LD devices. “Based on the information available to the company to date, including multiple discussions with the FDA, the company no longer anti...
Source: Mass Device - March 22, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Abiomed Inc. Source Type: news

FDA Panel Recommends Abbott's Absorb Bioresorbable Vascular Scaffold for Approval
This is the first installment of a two part feature regarding current thinking about the Bioresorbable Vascular Scaffold. Part One discusses the history and some general background issues surrounding the device; Part Two (to be posted later this week) consists of comments from leading interventional cardiologists about the current and future implications, predictions, critiques, and recommendations for the utilization of BVS. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 22, 2016 Category: Cardiology Source Type: news

St. Jude Medical Secures CE Mark Approval of MRI Compatibility for the Nanostim Leadless Pacemaker
St. Jude Medical, Inc. (NYSE:STJ) today announced CE Mark approval for magnetic resonance (MR) conditional labeling for 1.5 T scans for the company’s Nanostim™ leadless pacemaker. With the approval, throughout Europe both existing patients implanted with a Nanostim leadless pacemaker and new patients receiving a Nanostim leadless pacemaker in the future can safely undergo full-body MRI diagnostic scans. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 19, 2016 Category: Cardiology Source Type: news

Coronary artery disease: Angioplasty or bypass surgery?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - March 19, 2016 Category: Consumer Health News Source Type: news

UPDATE: FDA panel OKs Abbott’s Absorb stent
UPDATED March 16 with comments from panel members. An FDA advisory panel recommended approval for the Absorb bioresorbable stent made by Abbott (NYSE:ABT). The Circulatory Devices panel voted 9-1 on safety, 10-0 on efficacy and 9-1 on the risk-benefit profile for the Absorb device, a coronary scaffold that’s designed to elute the drug everolimus before dissolving entirely over a period of months. The FDA is not bound to follow the recommendations of its advisory panel but often does. “I do believe this is a novel breakthrough technology for patients undergoing [percutaneous coronary intervention],&rdq...
Source: Mass Device - March 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Clearance Stents Abbott Source Type: news

Abbott's Absorb™, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
Abbott (NYSE: ABT) announced today that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting coronary stent outweigh the risks. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 15, 2016 Category: Cardiology Source Type: news

Abbott's Absorb ™, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
Abbott (NYSE: ABT) announced today that an independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting coronary stent outweigh the risks. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 15, 2016 Category: Cardiology Source Type: news

Medtronic Begins CoreValve™ Evolut™ R "Real World" TAVR Study
Medtronic plc (NYSE: MDT) has announced the start of a new "real world" study of its CoreValve Evolut R transcatheter aortic valve. The first patients were enrolled at University Hospital in Bonn, Germany. The FORWARD study will enroll up to 1,000 patients at 60 centers worldwide. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 7, 2016 Category: Cardiology Source Type: news

Medtronic Begins CoreValve ™ Evolut™ R "Real World" TAVR Study
Medtronic plc (NYSE: MDT) has announced the start of a new "real world" study of its CoreValve Evolut R transcatheter aortic valve. The first patients were enrolled at University Hospital in Bonn, Germany. The FORWARD study will enroll up to 1,000 patients at 60 centers worldwide. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 7, 2016 Category: Cardiology Source Type: news

Pete Nicholas to Retire as Boston Scientific Board Chairman
Major medical device company Boston Scientific (NYSE:BSX) has announced that Pete Nicholas, its long-serving Chairman of the Board of Directors and co-founder, will formally retire from the Board in May. Founded almost four decades ago by Nicholas and John Abele, who met at their sons' soccer game in Massachusetts, Boston Scientific became one of the leading manufacturers of medical devices used in the interventional treatment of heart disease, stroke and more. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 7, 2016 Category: Cardiology Source Type: news

Leading hospital faces regular scrutiny over heart surgery death rates
Birmingham's Queen Elizabeth Hospital must submit weekly reports on heart surgery to the CQCRelated items from OnMedicaPatients should 'ignore' hospital death rate measuresStandardised mortality ratio should not be used as an indicator of avoidable deathsBlood thinners reduce angioplasty mortalitySelf-managing anticoagulants may cut risks after surgery (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 5, 2016 Category: UK Health Source Type: news

Studying for USMLE Step 2? Master this most missed question
Studying for the United States Medical Licensing Examination® (USMLE®) Step 2 may seem daunting, but not to fear. Starting this month, we’re giving you an exclusive scoop on the most missed USMLE Step 2 test prep questions and expert strategies to help you beat them. Check out this month’s most challenging question, and view an expert video explanation of the answer from Kaplan Medical. Welcome to the first Step 2 post in AMA Wire’s® series, “Tutor talk: Tips from Kaplan Medical on the most missed USMLE test prep questions from Kaplan’s Qbank.” Each month, we’re ...
Source: AMA Wire - February 24, 2016 Category: Journals (General) Authors: Amy Farouk Source Type: news

FDA Approves New CoreValve Low-Risk TAVR Study
Medtronic (NYSE: MDT) has announced FDA approval for a new study of transcatheter aortic valve replacement (TAVR). But this trial is different; this trial will be in patients at low-risk for the standard surgical procedure (SAVR). The device will be Medtronic's latest TAVR iteration, the CoreValve® Evolut® R, approved last June by the FDA, and will include 1,200 patients at up to 80 sites. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 24, 2016 Category: Cardiology Source Type: news

Younger Female Heart Patients More Likely to Need Follow-Up Care
TUESDAY, Feb. 23, 2016 -- Women under 50 who've been treated once for heart disease seem to fare worse than similarly treated men, a new report shows. Younger women who'd already had a procedure known as angioplasty to open their heart arteries... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 23, 2016 Category: Journals (General) Source Type: news

Medtronic Receives CE Mark for Full Line of Cardiac Resynchronization Therapy-Defibrillators Compatible with MRI Scans
Medtronic plc (NYSE:MDT) today announced that it has received CE (Conformité Européenne) Mark for the first and only cardiac resynchronization therapy defibrillators (CRT-Ds) approved for 3 Tesla (T) magnetic resonance imaging (MRI) scans, providing CRT-D patients with access to the most advanced imaging diagnostic procedures available. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 23, 2016 Category: Cardiology Source Type: news

CE Mark for Boston Scientific's Eluvia Peripheral Stent
Boston Scientific (NYSE: BSX) announced this morning that its Eluvia™ Drug-Eluting Vascular Stent has received the CE Mark for use in treating peripheral artery disease in the superficial femoral and proximal popliteal arteries. The company states that the Eluvia is the first polymer-based DES approved in Europe for use in the peripheral arteries. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 23, 2016 Category: Cardiology Source Type: news

Nipro launches 2nd-gen guidewire, OTW balloon cath in U.S.
This article originally appeared on MassDevice.com’s sister site, Medical Design & Outsourcing. The post Nipro launches 2nd-gen guidewire, OTW balloon cath in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 19, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Nipro Source Type: news

Nipro Medical Corporation launches the Cronus(TM) HP 0.035" OTW PTA Balloon Catheter in the United States
BRIDGEWATER, N.J., Feb. 19, 2016 -- (Healthcare Sales & Marketing Network) -- Nipro North America, a division of Nipro Medical Corporation, announced the launch of the Cronus HP high-pressure, 0.035" over-the-wire (OTW) percutaneous transluminal angi... Devices, Interventional, Product LaunchNipro Medical, Cronus HP, balloon catheter, angioplasty (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 19, 2016 Category: Pharmaceuticals Source Type: news

Meta-Analysis Shows Medtronic's Solitaire ™ Stent Retriever Device Improves Functional Outcomes for Acute Ischemic Stroke Patients; Reduced Mortality in Patients 80+
A meta-analysis published online today in Stroke and presented at the International Stroke Conference (ISC) in Los Angeles, Calif., found that the addition of Medtronic plc's (NYSE: MDT) Solitaire ™ stent retriever to current pharmaceutical treatment (IV-tPA) significantly improves functional outcomes in patients suffering stroke. The analysis also showed a significant reduction (20% vs. 40%, adjusted OR 3.7(1.3-10.6), p=0.01) in mortality for patients over the age of 80. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 18, 2016 Category: Cardiology Source Type: news

Meta-Analysis Shows Medtronic's Solitaire™ Stent Retriever Device Improves Functional Outcomes for Acute Ischemic Stroke Patients; Reduced Mortality in Patients 80+
A meta-analysis published online today in Stroke and presented at the International Stroke Conference (ISC) in Los Angeles, Calif., found that the addition of Medtronic plc's (NYSE: MDT) Solitaire™ stent retriever to current pharmaceutical treatment (IV-tPA) significantly improves functional outcomes in patients suffering stroke. The analysis also showed a significant reduction (20% vs. 40%, adjusted OR 3.7(1.3-10.6), p=0.01) in mortality for patients over the age of 80. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 18, 2016 Category: Cardiology Source Type: news

"Alarming" Increase in Heart Attacks Among Young Adults in India Due to Smoking and Lifestyle
"Stop Smoking!" is the heightened warning for young adults in India, based on a study presented today at the 67th Annual Conference of the Cardiological Society of India. The study looked at 310 patients who presented with acute coronary syndrome (ACS) during a two-year period to the Casualty (Emergency) Department of Sir Sunderlal Hospital. The frightening statistic is that the average age of these patients was 30 years old. The patients were almost all male, 90%, with the youngest ACS patient only 15 years of age. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 11, 2016 Category: Cardiology Source Type: news

New Real-World Comparison Showing Similar Efficacy Between the Lutonix ® and In.Pact™ Drug-Coated Balloons Featured at LINC 2016
Professor Dierk Scheinert, M.D., Head of the Department of Interventional Angiology at the University of Leipzig in Germany, commented, “These single-center results, like others before, show that real-world patients are benefiting from drug-coated balloon technology; and furthermore, the study indicates that there is no significant difference in the need for revascularization following treatment with either of these two DCBs.” (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 10, 2016 Category: Cardiology Source Type: news